CD130/gp130 antibody (pTyr905)
Quick Overview for CD130/gp130 antibody (pTyr905) (ABIN453269)
Target
See all CD130/gp130 (IL6ST) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- pTyr905
-
Specificity
- This antiobdy reacts to Tyr905 phosphorylated CD130 / IL6ST.
-
Purification
- Affinity chromatography on Protein A
-
Immunogen
- KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y905 of human IL6ST
-
-
-
-
Application Notes
-
ELISA: 1/1,000. Dot blot: 1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- CD130/gp130 (IL6ST) (Interleukin 6 Signal Transducer (Gp130, Oncostatin M Receptor) (IL6ST))
-
Alternative Name
- CD130 / IL6ST
-
Background
- IL6ST is a signal transducer shared by many cytokines, including interleukin 6 (IL6), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), and oncostatin M (OSM). This protein functions as a part of the cytokine receptor complex. The activation of this protein is dependent upon the binding of cytokines to their receptors. vIL6, a protein related to IL6 and encoded by the Kaposi sarcoma-associated herpesvirus, can bypass the interleukin 6 receptor (IL6R) and directly activate this protein.Synonyms: IL-6R-beta, IL6 receptor beta, Interleukin-6 receptor subunit beta
-
Gene ID
- 3572
-
NCBI Accession
- NP_002175
-
UniProt
- P40189
-
Pathways
- JAK-STAT Signaling, Cellular Glucan Metabolic Process, Autophagy, Smooth Muscle Cell Migration, Cancer Immune Checkpoints
Target
-